The Growing Burden of Glaucoma
Glaucoma is the second leading cause of vision loss worldwide, affecting more than 7.7 million people. It damages the optic nerve due to increased intraocular pressure. Current surgical treatments are often invasive, risky, and have limited durability.
The newly designed microstent is less than a quarter of a millimetre in diameter, allowing insertion with a standard hypodermic syringe. Once deployed, it expands within the eye to relieve pressure by improving fluid drainage.
Superior Results in Early Trials
In animal trials, the microstent lowered eye pressure within a month and produced better results than conventional tubular implants. Minimal inflammation and reduced scarring were also observed, increasing its potential long-term success.
Made from nitinol, a nickel-titanium alloy known for its durability and flexibility, the stent adapts to natural eye movement. Its unique design reduces the risk of migration and fibrosis, problems that limit current glaucoma implants.
Combining Engineering and Ophthalmology
The research team used advanced modelling techniques to ensure anatomical compatibility. Its superelastic structure maintains function as the eye changes over time, offering patients more reliable long-term outcomes.
By combining mechanical innovation with biocompatible materials, this glaucoma microstent represents a major advancement in minimally invasive glaucoma surgery (MIGS). Experts believe it could significantly improve quality of life for millions worldwide.
